The recent approval of BrightSpring Health Services’ (Nasdaq: BTSG) sale of its ResCare Community Living division to Sevita marks more than just a significant business transaction in the healthcare sector. Experts suggest the path to this $835 million deal—delayed by antitrust concerns and ultimately requiring Sevita to divest a portion of its holdings—could signal a shift in how the Federal Trade Commission (FTC) scrutinizes large-scale mergers and acquisitions within the industry. This case highlights the increasing focus on maintaining competition and protecting vulnerable patient populations as healthcare consolidation continues.
BrightSpring, a leading provider of home and community-based health services, initially entered into a definitive agreement with Sevita, another major player in the intellectual and developmental disabilities (IDD) services market, in January 2025 to divest its ResCare Community Living business. The agreement aimed to allow BrightSpring to concentrate on other areas of its business whereas Sevita expanded its reach. However, the FTC filed a complaint, raising concerns about potential anticompetitive practices. The core issue centered on overlapping services in specific geographic areas, particularly in Indiana, Louisiana and Texas, where both companies were primary providers of intermediate care facilities for individuals with IDD.
FTC Intervention and the Divestiture Requirement
The FTC’s intervention underscored its commitment to preventing monopolies and ensuring access to quality care, especially for individuals reliant on specialized services. According to the agreement reached with Sevita, the acquisition was permitted only after Sevita agreed to sell 126 intermediate care facilities—a slight discrepancy from the 128 initially reported—to the Dungarvin Group, a regional operator. This divestiture was designed to mitigate the potential for reduced competition and maintain service options for patients. The FTC’s action demonstrates a willingness to challenge even large transactions when they raise concerns about market dominance.
“There was competitive overlap in certain areas of the market, where, if the deal went through as proposed, it would have a materially negative impact on competition, meaning the the post-close entity would have so much control over that market in terms of delivery of care that it could have a negative impact on patients or payers,” explained attorney Anthony Del Rio with the law firm of Katten, Muchin and Rosenman, as reported by Home Health Care News. Del Rio further elaborated that excessive market control could lead to increased prices and potentially affect wages for healthcare workers.
Financial Implications and Operational Adjustments
The protracted approval process impacted BrightSpring’s financial reporting. In 2025, pending the sale, the ResCare business was classified as “discontinued operations,” effectively removing it from the company’s standard accounting procedures. Despite this classification, ResCare generated substantial revenue: $314.6 million in the third quarter of 2025 (ending September 30th) and $921.4 million from January 1st to September 20th, 2025. BrightSpring Health Services reported a total revenue of approximately $5.6 billion in 2024, according to their most recent filings. Investor Relations information details the company’s ongoing strategic focus on core service areas.
BrightSpring anticipates the divestiture to close in the first fiscal quarter of 2026, contingent upon fulfilling customary closing conditions. The company has framed the transaction as a strategic move to concentrate on a more focused group of customers and stakeholders. Sevita, meanwhile, is poised to expand its footprint in the IDD services sector, albeit with the requirement to manage the transition of the divested facilities to the Dungarvin Group. Sevita currently operates in 40 states, providing a range of home and community-based services.
Broader Implications for Healthcare M&A
The BrightSpring-Sevita deal is being closely watched as a potential bellwether for future healthcare mergers and acquisitions. The FTC’s scrutiny and the imposed divestiture requirement suggest a more assertive approach to antitrust enforcement in the sector. This could lead to more complex and lengthy approval processes for large transactions, particularly those involving companies with significant market overlap. The case also highlights the importance of considering the impact on vulnerable populations when evaluating the competitive effects of mergers.
The increased regulatory oversight may prompt companies to proactively address potential antitrust concerns before submitting deals for approval. This could involve offering voluntary divestitures or making commitments to maintain service levels in affected areas. The FTC’s actions may encourage greater transparency in the M&A process, with companies providing more detailed information about the potential impact on competition and patient access. The evolving regulatory landscape necessitates careful planning and a thorough understanding of antitrust principles for healthcare organizations considering mergers or acquisitions.
The Role of Intermediate Care Facilities
Intermediate care facilities (ICFs) play a crucial role in providing long-term care and support for individuals with intellectual and developmental disabilities. These facilities offer a range of services, including residential care, medical care, and rehabilitative therapies. The FTC’s concern over the concentration of ICF ownership reflects the importance of maintaining a diverse network of providers to ensure access to quality care and prevent potential abuses of market power. The Dungarvin Group, as the recipient of the divested facilities, will be responsible for ensuring continuity of care for the residents and maintaining the quality of services.
The number of individuals with IDD receiving services in ICFs varies by state, but nationally, it represents a significant portion of the long-term care population. According to data from the Administration for Community Living, approximately 8.3 million Americans have an intellectual or developmental disability. Maintaining a competitive market for ICF services is essential to ensure that individuals with IDD have access to the care and support they need to live fulfilling lives.
The BrightSpring-Sevita deal, and the FTC’s response, underscores a growing trend toward increased regulatory scrutiny of healthcare consolidation. As the industry continues to evolve, This proves likely that the FTC will continue to play a proactive role in protecting competition and ensuring access to affordable, high-quality care for all Americans. The finalization of this transaction, expected in early 2026, will be a closely watched event, potentially setting a precedent for future healthcare M&A activity.
The next key development will be the completion of the divestiture to the Dungarvin Group and the subsequent integration of those facilities into their operations. We will continue to monitor this situation and provide updates as they become available. What are your thoughts on the increasing regulatory scrutiny of healthcare mergers? Share your comments below.